Rheumatoid Arthritis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, OncoOne, Oryn Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rheumatoid Arthritis pipeline constitutes 75+ key companies continuously working towards developing 80+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Rheumatoid Arthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others, are developing therapies for the Rheumatoid Arthritis treatment
• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years
• In July 2024, Navidea Biopharma has decided to discontinue its rheumatoid arthritis (RA) program following unsatisfactory findings from an exploratory analysis of the NAV3-33 trial. The Phase III study (NCT05246280), which included 523 participants, aimed to validate the effectiveness of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical outcomes in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.
• In July 2024, Dutch biotech firm Citryll has completed subject dosing in the repeat-dose phase of its Phase I clinical trial for CIT-013, an anti-inflammatory drug candidate. This first-in-human study focuses on evaluating the safety and tolerability of the antibody. In the trial's part D segment, the safety and tolerability of CIT-013 are further assessed through repeat dosing in a group of nine rheumatoid arthritis (RA) patients and three healthy volunteers.

Rheumatoid Arthritis Overview
Rheumatoid Arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, swelling, and stiffness. Over time, it can lead to joint damage, deformity, and reduced mobility. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the lining of the joints, known as the synovium.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• SBT-77-7101: Sonoma Biotherapeutics
• ON104: OncoOne
• ORTD 1: Oryn Therapeutic
• TJ003234: I-Mab Biopharma Co. Ltd.
• TCK-276: Teijin Pharma
• IRL-201805: Revolo Biotherapeutics
• LY3462817: Eli Lilly and Company
• Dekavil: Philogen
• AP1189: SynAct Pharma
• RC18: RemeGen
• SM03: SinoMab Bioscience
• TS152: Taisho Pharmaceutical
• SM03: SinoMab
• SHR0302: Jiangsu Hengrui Medicine
• RC18: RemeGen
• Otilimab: GlaxoSmithKline
• ATI-450: Aclaris Therapeutics
• MBS2320: Modern Biosciences
• PF-06651600: Pfizer
• Obefazimod: Abivax
• ABBV-154: AbbVie
• Branebrutinib: Bristol Myers Squibb
• KPL-404: Kiniksa Pharmaceuticals
• ORTD-1: Oryn Therapeutics
• MRx0006: 4D pharma plc.
• LABP-69: Landos Biopharma, Inc
• BZ068: Biozeus

Rheumatoid Arthritis Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Rheumatoid Arthritis Molecule Type
Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight's Rheumatoid Arthritis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies at:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., and others.

Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies-
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers
• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA • Delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutic, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others
• Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM0, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Rheumatoid Arthritis Report Introduction
2. Rheumatoid Arthritis Executive Summary
3. Rheumatoid Arthritis Overview
4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Late Stage Products (Phase II/III)
7. Rheumatoid Arthritis Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Early Stage Products (Phase I)
9. Rheumatoid Arthritis Preclinical Stage Products
10. Rheumatoid Arthritis Therapeutics Assessment
11. Rheumatoid Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rheumatoid Arthritis Key Companies
14. Rheumatoid Arthritis Key Products
15. Rheumatoid Arthritis Unmet Needs
16 . Rheumatoid Arthritis Market Drivers and Barriers
17. Rheumatoid Arthritis Future Perspectives and Conclusion
18. Rheumatoid Arthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Rheumatoid Arthritis Market https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Rheumatoid Arthritis Epidemiology https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Rheumatoid Arthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.